CN107375195A - A kind of periodontal topical remedy sustained-release hydrogel and its application based on chitosan - Google Patents
A kind of periodontal topical remedy sustained-release hydrogel and its application based on chitosan Download PDFInfo
- Publication number
- CN107375195A CN107375195A CN201710535065.XA CN201710535065A CN107375195A CN 107375195 A CN107375195 A CN 107375195A CN 201710535065 A CN201710535065 A CN 201710535065A CN 107375195 A CN107375195 A CN 107375195A
- Authority
- CN
- China
- Prior art keywords
- chitosan
- aspirin
- hydrogel
- epo
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Dental Preparations (AREA)
Abstract
A kind of periodontal topical remedy sustained-release hydrogel and its application based on chitosan, belong to topical remedy's slow-released carrier preparing technical field.More particularly to the chitosan solution containing aspirin, β phosphoglycerol sodium solution and gelatin solution containing EPO is prepared, three kinds of solution obtain carrying aspirin and EPO chitosan temperature-sensitive hydrogel after mixing at 34~40 DEG C in proportion.Load aspirin and EPO chitosan temperature-sensitive hydrogel surface apertures prepared by this method is about 40~70 μm, can gelation at 34~40 DEG C；In the rat maxillary first molar Periodontitis Model using ligature structure, the local injection hydrogel can control periodontal disease and promote the regeneration of periodontium.Therefore, using chitosan sodium glycero-phosphate gelatin injecting temperature sensitive type hydrogel as local application's slow-released carrier of periodontitis treatment, while anti-inflammatory drug aspirin and EPO are loaded, there is preferable application value and prospect.
Description
Technical field
The invention belongs to topical remedy's slow-released carrier preparing technical field, and in particular to a kind of temperature sensitive type based on chitosan
Hydrogel, the hydrogel are applied topically to periodontitis mould by compound with medicine aspirin and hematopoietin (EPO)
Type, periodontal disease can either be controlled, and can enough promotes paradenlal tissue regeneration, thus a kind of periodontal topical remedy can be used as to be sustained
System, applied to the drug therapy after periodental non-surgical treatment.
Background technology
Periodontitis is the diseases associated with inflammation caused by interaction complicated between bacterial plaque microorganism and host immune system, by tooth
Absorption of alveolar bone caused by Zhou Yan is the first reason that adult loses tooth.There are some researches show periodontitis not only results in the forfeiture of tooth,
Whole body system health can be also influenceed simultaneously.As periodontitis pathogenic bacteria, porphyromonas gingivalis (porphyromonas
Gingivalis, Pg) change of gut flora can be triggered, cause the increase of enteric epithelium permeability, and trigger system inflammation and lead
Cause endotoxemia generation, and then add suffer from atherosclerosis, Averse pregnancy outcomes (premature, infant of low-birth weight etc.),
The risk of rheumatic arthritis, aspiration pneumonia and cancer etc..Therefore, periodontitis and the health and quality of life of the mankind
It is closely related.Existing periodontal treatment means such as periodental non-surgical treatment, flap operation, autologous bone transplanting art, and guiding tissue is again
Raw art (guided tissue regeneration, GTR) etc. is only capable of reducing oral pocket and depth, portion are examined in the spy of furcation area infringement
Divide and recover periodontal attachment, and the periodontium that can not promote to be destroyed recovers its physiological structure and function completely.Therefore, find
One kind can control periodontal disease, and can further realize that paradenlal tissue regeneration and the treatment means of reparation are still the field face
World-class problem.
The key of periodontitis treatment, on the one hand it is to suppress periodontal disease；On the other hand it is to promote paradenlal tissue regeneration, and shows
It is difficult to realize above-mentioned requirements simultaneously to have treatment method.Inflammatory reaction caused by Periodontal Pathogens causes the destruction of periodontium.
There are some researches prove aspirin (Aspirin) suppresses inflammation by PI3K/Akt, ERK and NF- κ B signal paths, and promotees
Erythropoietin(EPO) (EPO) can promote cell propagation and bon e formation.Therefore, periodontal disease is suppressed with Aspirin, EPO promotes
Paradenlal tissue regeneration is expected to treat periodontitis.
Inflammatory periodontal tissue defect is mostly irregular, and the gel of solution state can easily fill each position of defect
Point.After gel solidification, it is possible to provide space maintains and the sustained-release activity factor.Chitosan-sodium glycero-phosphate-gelatin temperature-sensitive hydrogel
It is biodegradable, and catabolite has no toxic side effect, therefore implantation material is taken out without second operation, there is body environment
The characteristics of friendly.In addition, chitosan has antagonistic property, help to control periodontitis local microenvironment；Sodium glycero-phosphate conduct
One of osteogenic induction liquid composition, moreover it is possible to promote cell skeletonization to differentiation；Gelatin is rich in collagen component, has supplement inflammation degraded
The ability of extracellular matrix and induced osteogenesis.To sum up, made with chitosan-sodium glycero-phosphate-gelatin injecting temperature sensitive type hydrogel
For local application's slow-released carrier of periodontitis treatment, while anti-inflammatory drug aspirin and EPO are loaded, before there is preferably research
Scape and application value.
The content of the invention
It is an object of the invention to provide a kind of periodontal topical remedy sustained-release hydrogel based on chitosan and its application.It is logical
Cross compound with conventional medicament aspirin and hematopoietin, the local inflammation of Periodontitis Model can not only be controlled anti-
Should, while the regeneration of periodontium can also be promoted, it is expected to realize the target of paradenlal tissue regeneration reparation.
Aspirin is dissolved in hydrochloric acid solution and dissolved the chitosan in this solution by early stage of the invention, and EPO is dissolved in sweet
In the aqueous solution of oleophosphoric acid sodium, make it at a certain temperature by adding gelatin solution, rapid cross-linked gel obtains carrying Ah Si
Woods and the temperature-sensitive hydrogel of hematopoietin, surface apertures are about 40~70 μm.The load liquid medicine gel rubber system is local
After Periodontitis Model, periodontal disease can be controlled and promote the regeneration of periodontium.
The raw material that the present invention uses all is the commercial material that can directly buy, it is not necessary to further processing, according to one
Certainty ratio directly mixes, therefore experimental implementation is easy, dangerous small, and has good experimental repeatability, can criticize
Amount production, while there is the characteristics of body environment close friend.
It is of the present invention that aspirin and EPO temperature-sensitive hydrogel preparation are carried based on chitosan, can be by following
Step obtains：(1) preparation and purifying of each ingredient solution；(2) load aspirin and EPO chitosan temperature-sensitive hydrogel is solidifying
Gel.
(1) preparation of hydrogel each component solution：20~40mg aspirin is added to 20~40mL 0.1mol/L
In hydrochloric acid solution, and 0.4~0.8g chitosan is added, be uniformly mixing to obtain the chitosan solution containing aspirin；Again by 1~
2g sodium β-glycerophosphate is added in 2~4mL deionized water, and adds 6000~10000U hematopoietin
EPO, it is uniformly mixing to obtain the sodium β-glycerophosphate solution of the EPO containing hematopoietin；20~100mg gelatin is added to 10
In~20mL deionized water, gelatin solution is uniformly mixing to obtain；
(2) gelation of aspirin and EPO chitosan temperature-sensitive hydrogel is carried：To shells of the 2~4mL containing aspirin
The sodium β-glycerophosphate solution and gelatin solution of the EPO containing hematopoietin are added dropwise in glycan solution, after stirring,
It is placed in 34~40 DEG C of thermostat water bath and carries out gel, so as to obtains a kind of periodontal office based on chitosan of the present invention
Portion's medicament slow release hydrogel；The volume ratio of three kinds of solution is 8~12：1~3：0.25~1.
Brief description of the drawings
Fig. 1：The periodontal topical remedy sustained-release hydrogel stereoscan photograph based on chitosan prepared, show prepared
Hydrogel surface aperture is about 40~70 μm；
Fig. 2：Periodontal Tissues of Rat Periodontitis animal model schematic diagram, periodontitis is established at rat maxillary first molar using ligature
Model；
Fig. 3：The load aspirin of preparation and EPO chitosan temperature-sensitive hydrogel are applied to Periodontal Tissues of Rat Periodontitis animal model
Conical beam CT (Cone beam CT, CBCT) picture afterwards.(a) it is blank control group, (b) periodontitis modeling group, (c) is periodontal
Inflammation+hydrogel group, (d) are periodontitis+hydrogel+aspirin group, and (e) is periodontitis+hydrogel+EPO groups, and (f) is periodontal
Inflammation+hydrogel+aspirin+EPO groups.Wherein, blank control group is without obvious bone information；Periodontitis group absorption of alveolar bone is obvious,
Crest of alveolar ridge significantly increases to amelocemental junction distance；Periodontitis+hydrogel+aspirin+EPO group absorption of alveolar bone degree
It is obvious to be lighter than for periodontitis+hydrogel+aspirin group and be periodontitis+hydrogel+EPO groups；
Fig. 4：The load aspirin of preparation and EPO chitosan temperature-sensitive hydrogel are applied to Periodontal Tissues of Rat Periodontitis animal model
Haematine-eosin staining procedures (hematoxylin-eosin staining, HE) picture afterwards.(a, g) is blank control group,
Wherein, the partial enlargement that (g) is (a) square areas is schemed；(b, h) periodontitis modeling group, figure (h) are the part of (b) square areas
Amplification；(c, i) is periodontitis+hydrogel group, and figure (i) is the partial enlargement of (c) square areas；(d, j) is periodontitis+hydrogel
+ aspirin group, figure (j) are the partial enlargement of (d) square areas；(e, k) is periodontitis+hydrogel+EPO groups, and figure (k) is
(e) partial enlargement of square areas；(f, l) is periodontitis+hydrogel+aspirin+EPO groups, and figure (l) is (f) square areas
Partial enlargement.Wherein, blank control group is without obvious inflammatory reaction and periodontal tissue destruction；The visible thicker inflammation of periodontitis group is thin
Born of the same parents' soakage layer, periodontal tissue destruction are obvious；Periodontitis+hydrogel+aspirin group and periodontitis+hydrogel+aspirin+
The only visible a small amount of cell infiltration of EPO groups；Periodontitis+hydrogel+aspirin+EPO group turn back lines are obvious.
Embodiment
With reference to embodiment, the present invention is further elaborated, rather than to be limited the invention with this.
Embodiment 1
(1) preparation of hydrogel each component solution：20mg aspirin (Sigma Co., USA) is added to 20mL's
In 0.1mol/L hydrochloric acid (Beijing Chemical Plant) solution, and 0.4g chitosan (Sigma Co., USA) is added, be uniformly mixing to obtain
Chitosan solution containing aspirin.1g sodium β-glycerophosphate (Sigma Co., USA) is added to 2mL deionized water
In, and 6000U EPO (Chinese three lives pharmaceutcal corporation, Ltd) are added, it is uniformly mixing to obtain the sodium β-glycerophosphate solution containing EPO.
20mg gelatin (Sigma Co., USA) is added in 10mL deionized water, is uniformly mixing to obtain gelatin solution.
(2) gelation of aspirin and EPO chitosan temperature-sensitive hydrogel is carried：Take 2mL above-mentioned containing aspirin
Chitosan solution, by volume example 8：1：0.25 is added dropwise on the above-mentioned sodium β-glycerophosphate solution of 0.25mL and 62.5 μ L and states clearly
Sol solution, after stirring, be placed in 35 DEG C of thermostat water baths, after 829s ± 26s gelation obtain carrying aspirin and EPO
Chitosan temperature-sensitive hydrogel.
After above-mentioned hydrogel is lyophilized, it is about 40~70 μ that visible resulting hydrogel surface aperture is observed under ESEM
M, as shown in Figure 1.
Embodiment 2
(1) preparation of hydrogel each component solution：40mg aspirin is added to 40mL 0.1mol/L hydrochloric acid solutions
In, and 0.8g chitosan is added, it is uniformly mixing to obtain the chitosan solution containing aspirin.2g sodium β-glycerophosphate is added
Enter into 4mL deionized water, and add 10000U EPO, be uniformly mixing to obtain the sodium β-glycerophosphate solution containing EPO.Will
100mg gelatin is added in 20mL deionized water, is uniformly mixing to obtain gelatin solution.
(2) gelation of aspirin and EPO chitosan temperature-sensitive hydrogel is carried：The above-mentioned chitosan solutions of 4mL are taken, are pressed
12：3：1 volume ratio, gelatine solution on the above-mentioned sodium β-glycerophosphate solution of 1mL and 333 μ L is added dropwise, stirs
Afterwards, it is respectively placed in 33 DEG C, 34 DEG C, 35 DEG C, 36 DEG C, 37 DEG C, 38 DEG C and 40 DEG C of thermostat water bath, detects it in different temperatures
Under gelation time.Test result indicates that under different temperatures the aquogel system gelation time, parallel laboratory test repeat 3
It is secondary.Not gel when prepared water gel ties up to 33 DEG C, gel time is 40min37s ± 40s at 34 DEG C, gel at 35 DEG C
Time is 829s ± 26s, and gel time is 390s ± 10s at 36 DEG C, and gel time is 230s ± 15s at 37 DEG C, 38 DEG C of gels
Time is 198s ± 23s, and gel time is 179s at 40 DEG C.
Embodiment 3
(1) preparation of hydrogel each component solution：30mg aspirin is added to 30mL 0.1mol/L hydrochloric acid solutions
In, and 0.5g chitosan is added, it is uniformly mixing to obtain the chitosan solution containing aspirin.By 1.5g sodium β-glycerophosphate
It is added in 3mL deionized water, and adds 8000U EPO, is uniformly mixing to obtain the sodium β-glycerophosphate solution containing EPO.Will
50mg gelatin is added in 15mL deionized water, is uniformly mixing to obtain gelatin solution.
(2) gelation of aspirin and EPO chitosan temperature-sensitive hydrogel is carried：The above-mentioned chitosan solutions of 3mL are taken, are pressed
10：2：0.5 volume ratio, gelatine solution on the above-mentioned sodium β-glycerophosphate solution of 0.6mL and 150 μ L is added dropwise, stirs
Uniformly.
(3) for investigate the load aspirin and EPO chitosan temperature-sensitive hydrogel to the control action of periodontal disease and
Promoting regeneration of periodontal tissue acts on, and constructs Periodontal Tissues of Rat Periodontitis Model.We choose male Wistar rat (body weight 200~
250g), with after chloraldurate (20mg/kg, chloraldurate/rat body weight) aqueous solution anesthesia of mass fraction 10%, tooth is separated
Gum is ligatured and fixed to bone face for 1 week with ligature around maxillary first molar after palate side.Simultaneously in the near and far alveolus of first molar
Hydrogel solution in 20 μ L steps (2) is respectively injected at ridge top, every 3 days once, continuous 7 days.
Constructed Periodontal Tissues of Rat Periodontitis Model schematic diagram is as shown in Fig. 2 in the visible ligature of maxillary first molar.
Embodiment 4
(1) preparation of aspirin and EPO chitosan temperature-sensitive hydrogel is carried as described in Example 3.
(2) for investigate the load aspirin and EPO chitosan temperature-sensitive hydrogel to the control action of periodontal disease and
Promoting regeneration of periodontal tissue acts on, and constructs Periodontal Tissues of Rat Periodontitis Model, and local injection carries aspirin and EPO chitosan is temperature sensitive
Type hydrogel.Phosphate buffered saline solution (the phosphate buffer of the paraformaldehyde of mass fraction 4% are used after 7 days
Saline, PBS) cardiac perfusion fixation execution, maxillary alveolar bone is taken, CBCT observes normal rat crest of alveolar ridge to enamel dentale
The absorption of alveolar bone destroys after the distance of matter circle, and modeling.And local injection is investigated and has carried aspirin chitosan temperature sensitive type
Hydrogel, carry EPO chitosans temperature-sensitive hydrogel and carry aspirin and EPO chitosan temperature-sensitive hydrogel to alveolar bone
Absorb the distance of the influence, i.e. crest of alveolar ridge to amelocemental junction that destroy.
Such as Fig. 3, shown in CBCT pictures, without obvious bone information, crest of alveolar ridge to enamel around blank control group first molar
Cementum circle distance is 0.56 ± 0.07mm.Periodontitis group first molar and the closely middle absorption of alveolar bone of second molar are obvious, alveolus
Ridge top to amelocemental junction distance be 1.82 ± 0.19mm.Compared with periodontitis group, hydrogel group, aspirin hydrogel is carried
Group and load EPO hydrogel groups absorption of alveolar bone are slightly alleviated, and crest of alveolar ridge to amelocemental junction distance respectively 1.51 ±
0.29mm, 1.07 ± 0.18mm and 1.23 ± 0.98mm.Carry aspirin and EPO hydrogel group absorption of alveolar bone destructiveness most
Gently, destroyed without obvious absorption of alveolar bone, crest of alveolar ridge to amelocemental junction distance is 0.73 ± 0.09mm.
Embodiment 5
(1) preparation of aspirin and EPO chitosan temperature-sensitive hydrogel is carried as described in Example 3.
(2) for investigate the load aspirin and EPO chitosan temperature-sensitive hydrogel to the control action of periodontal disease and
Promoting regeneration of periodontal tissue is acted on, and in addition to sample is carried out into CBCT detections, the sample after detection is placed in the second of mass fraction 15%
The PBS solution decalcification of ethylenediamine tetraacetic acid (EDTA) (Ethylenediaminetetraacetic acid, EDTA) 2 months, is then consolidated
Fixed, dehydration and histological stain step by step, clearly to carry whether the chitosan temperature-sensitive hydrogel of aspirin and EPO can control
Periodontal disease simultaneously promotes paradenlal tissue regeneration.
As shown in figure 4, micro- Microscopic observation is visible, and blank control group parodontium and cementum structural integrity, no destruction, tooth
Sharp nipple is intact, and alveolar bone is without absorption, periodontal membrane fiber aligned orderly.Periodontitis group inflammatory reaction is obvious, and neutrophil leucocyte increases
It is more, it is seen that lymphocyte, plasmocyte infiltrating, blood vessel dilatation is congested, absorption of alveolar bone to apical area, it is seen that sequestrum.Hydrogel group
Visible a small amount of cell infiltration in gingival epithelium, while visible turn back line, illustrate there is bone remodeling.Carry aspirin hydrogel
Group inflammatory reaction unobvious, turn back line are obvious.Carry visible neutrophil leucocyte in EPO hydrogel group fibr tissues, absorption of alveolar bone
Unobvious, no sequestrum are formed, it is seen that turn back line.Load aspirin and EPO chitosan temperature-sensitive hydrogel group inflammatory reaction are not
Substantially, rarely seen a small amount of cell infiltration, it is seen that newborn braided bone tissue, the visible turn back line in furcation area area, illustrate bone remodeling
It is active.
Claims (2)
- A kind of 1. periodontal topical remedy sustained-release hydrogel based on chitosan, it is characterised in that：It is prepared into by following steps Arrive,(1) preparation of hydrogel each component solution：20~40mg aspirin is added to 20~40mL 0.1mol/L hydrochloric acid In solution, and 0.4~0.8g chitosan is added, be uniformly mixing to obtain the chitosan solution containing aspirin；Again by 1~2g's Sodium β-glycerophosphate is added in 2~4mL deionized water, and adds 6000~10000U hematopoietin, stirring Uniformly obtain the sodium β-glycerophosphate solution containing hematopoietin；20~100mg gelatin is added to going for 10~20mL In ionized water, gelatin solution is uniformly mixing to obtain；(2) gelation of aspirin and EPO chitosan temperature-sensitive hydrogel is carried：To chitosans of the 2~4mL containing aspirin Sodium β-glycerophosphate solution and gelatin solution containing hematopoietin are added dropwise in solution, after stirring, is placed in 34 Gel is carried out in~40 DEG C of thermostat water bath, so as to obtain the periodontal topical remedy sustained-release hydrogel based on chitosan；Three kinds The volume ratio of solution is 8~12：1~3：0.25~1.
- 2. a kind of periodontal topical remedy sustained-release hydrogel based on chitosan described in claim 1 is in control periodontal disease, rush The application entered in paradenlal tissue regeneration.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710535065.XA CN107375195A (en) | 2017-07-04 | 2017-07-04 | A kind of periodontal topical remedy sustained-release hydrogel and its application based on chitosan |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710535065.XA CN107375195A (en) | 2017-07-04 | 2017-07-04 | A kind of periodontal topical remedy sustained-release hydrogel and its application based on chitosan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375195A true CN107375195A (en) | 2017-11-24 |
Family
ID=60334291
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710535065.XA Pending CN107375195A (en) | 2017-07-04 | 2017-07-04 | A kind of periodontal topical remedy sustained-release hydrogel and its application based on chitosan |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375195A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110279654A (en) * | 2019-07-22 | 2019-09-27 | 苏州大学附属第一医院 | It is sustained aspirin liposome hydrogel, preparation method and its application in preparation treatment recurrent lumbar disc herniation after discectomy drug |
| SE2150302A1 (en) * | 2021-03-17 | 2022-09-18 | Labrida As | Prevention and treatment of periodontal and peri-implant disease |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1494921A (en) * | 2002-07-18 | 2004-05-12 | 维奥（四川）生物技术有限公司 | Erythropoietin oral lozenge and its preparation method |
| CN105342989A (en) * | 2015-12-14 | 2016-02-24 | 天津医科大学口腔医院 | Aspirin-encapsulated nano-microsphere composite temperature-sensitive gel slow-release inhibitor |
-
2017
- 2017-07-04 CN CN201710535065.XA patent/CN107375195A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1494921A (en) * | 2002-07-18 | 2004-05-12 | 维奥（四川）生物技术有限公司 | Erythropoietin oral lozenge and its preparation method |
| CN105342989A (en) * | 2015-12-14 | 2016-02-24 | 天津医科大学口腔医院 | Aspirin-encapsulated nano-microsphere composite temperature-sensitive gel slow-release inhibitor |
Non-Patent Citations (3)
| Title |
|---|
| C. LI1*,ETAL: "Erythropoietin Promotes Bone Formation through EphrinB2/EphB4 Signaling", 《RESEARCH REPORTS: BIOLOGICAL》 * |
| 孙宏晨 等: "载促红细胞生成素壳聚糖温敏水凝胶促兔提升上颌窦骨再生作用", 《2016年国际口腔及颅颌前沿研究研讨会暨全国口腔生物医学年会论文汇编》 * |
| 顾中一 等: "载EPO 和Aspirin壳聚糖水凝胶的制备与表征", 《载EPO 和ASPIRIN壳聚糖水凝胶的制备与表征》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110279654A (en) * | 2019-07-22 | 2019-09-27 | 苏州大学附属第一医院 | It is sustained aspirin liposome hydrogel, preparation method and its application in preparation treatment recurrent lumbar disc herniation after discectomy drug |
| SE2150302A1 (en) * | 2021-03-17 | 2022-09-18 | Labrida As | Prevention and treatment of periodontal and peri-implant disease |
| SE545090C2 (en) * | 2021-03-17 | 2023-03-28 | Labrida As | A hydrogel comprising chitosan for use in prevention and treatment of periodontal and peri-implant disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Shimizu et al. | Histologic observation of a human immature permanent tooth with irreversible pulpitis after revascularization/regeneration procedure | |
| Faraco Jr et al. | Response of the pulp of dogs to capping with mineral trioxide aggregate or a calcium hydroxide cement | |
| Torabinejad et al. | Revitalization of tooth with necrotic pulp and open apex by using platelet-rich plasma: a case report | |
| Narang et al. | A comparative evaluation of the blood clot, platelet-rich plasma, and platelet-rich fibrin in regeneration of necrotic immature permanent teeth: a clinical study | |
| Wang et al. | The miniature pig: a useful large animal model for dental and orofacial research | |
| Bezgin et al. | Concentrated platelet‐rich plasma used in root canal revascularization: 2 case reports | |
| Parolia et al. | A comparative histological analysis of human pulp following direct pulp capping with Propolis, mineral trioxide aggregate and Dycal | |
| Geisler | Clinical considerations for regenerative endodontic procedures | |
| Palma et al. | Does apical papilla survive and develop in apical periodontitis presence after regenerative endodontic procedures? | |
| Jayawardena et al. | Pulpal response to exposure with Er: YAG laser | |
| Shiehzadeh et al. | Healing of large periapical lesions following delivery of dental stem cells with an injectable scaffold: new method and three case reports | |
| Gottberg et al. | Prenatal effects by exposing to amoxicillin on dental enamel in Wistar rats | |
| Fekrazad et al. | The effect of low-level laser therapy (810 nm) on root development of immature permanent teeth in dogs | |
| CN107375195A (en) | A kind of periodontal topical remedy sustained-release hydrogel and its application based on chitosan | |
| Young et al. | A randomised, controlled and blinded histological and immunohistochemical investigation of Carisolv™ on pulp tissue | |
| Walton et al. | Migration of materials in the dental pulp of monkeys | |
| Suresh et al. | Successful regenerative endodontic procedure of a nonvital immature permanent central incisor using amniotic membrane as a novel scaffold | |
| Song et al. | Abalone‐inspired adhesive and photo‐responsive microparticle delivery systems for periodontal drug therapy | |
| Somani et al. | Platelet rich plasma—a healing aid and perfect enhancement factor: review and case report | |
| Chiang et al. | A mesoporous biomaterial for biomimetic crystallization in dentinal tubules without impairing the bonding of a self-etch resin to dentin | |
| Abbas et al. | Experimental gingivitis in relation to susceptibility to periodontal disease II. Phase‐contrast microbiological features and some host‐response observations | |
| Petrescu et al. | Platelet rich fibrin as a gingival tissue regeneration enhancer | |
| Selahi et al. | The Appliance of A-PRF and CGF in the Treatment of Impacted Mandibular Third Molar Extraction Sockets—Narrative Review | |
| Da Silva et al. | Surgical alternative for treatment of vertical root fracture: a case report | |
| Nowak-Wachol et al. | Yttrium trifluoride as a marker of infiltration rate of decalcified root cementum: An in vitro study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171124 |